Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research.

Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD.

Curr Pharm Des. 2012;18(11):1543-55. Review.

PMID:
22364138
2.

Platelets in rheumatic diseases: friend or foe?

Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD.

Curr Pharm Des. 2014;20(4):552-66. Review.

PMID:
23565634
3.

Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.

Nandi P, Kingsley GH, Scott DL.

Curr Opin Rheumatol. 2008 May;20(3):251-6. doi: 10.1097/BOR.0b013e3282fb7caa. Review.

PMID:
18388514
4.

An update on methotrexate.

Braun J, Rau R.

Curr Opin Rheumatol. 2009 May;21(3):216-23. doi: 10.1097/BOR.0b013e328329c79d. Review.

PMID:
19373092
5.

Pharmacoepidemiology and rheumatic diseases: 2001-2002.

Solomon DH, Avorn J.

Curr Opin Rheumatol. 2003 Mar;15(2):122-6. Review.

PMID:
12598798
6.

Disease-modifying antirheumatic drugs.

Conaghan PG, Lehmann T, Brooks P.

Curr Opin Rheumatol. 1997 May;9(3):183-90. Review.

PMID:
9204252
7.

The perioperative use of biologic agents in patients with rheumatoid arthritis.

Polachek A, Caspi D, Elkayam O.

Autoimmun Rev. 2012 Dec;12(2):164-8. doi: 10.1016/j.autrev.2012.04.001. Epub 2012 Apr 12. Review.

PMID:
22522087
8.

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.

Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S.

Arthritis Rheum. 2006 Dec;54(12):3790-8.

9.

Innovative treatment approaches for rheumatoid arthritis. Combination therapy.

Borigini MJ, Paulus HE.

Baillieres Clin Rheumatol. 1995 Nov;9(4):689-710. Review.

PMID:
8591649
10.
11.

[Cardiovascular comorbidity in rheumatic disease. Does sex play a role?].

Kung M, Störk S, Angermann CE.

Herz. 2005 Sep;30(6):512-21. Review. German.

PMID:
16170682
12.

Drugs in pregnancy. Rheumatological disorders.

Østensen M.

Best Pract Res Clin Obstet Gynaecol. 2001 Dec;15(6):953-69. Review.

PMID:
11800535
13.

Therapeutic options for rheumatoid arthritis.

Feely MG, Erickson A, O'Dell JR.

Expert Opin Pharmacother. 2009 Sep;10(13):2095-106. doi: 10.1517/14656560903071043. Review.

PMID:
19606939
14.

Juvenile idiopathic arthritis - an update on pharmacotherapy.

Kahn P.

Bull NYU Hosp Jt Dis. 2011;69(3):264-76. Review.

15.

Anti-cytokine antibodies for rheumatic diseases.

Atzeni F, Sarzi-Puttini P.

Curr Opin Investig Drugs. 2009 Nov;10(11):1204-11. Review.

PMID:
19876788
16.

Autologous bone marrow transplantation versus alternative drugs in pediatric rheumatic diseases.

Lepore L, Kiren V.

Haematologica. 2000 Nov;85(11 Suppl):89-92. Review.

PMID:
11268332
17.

[Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients].

Gómez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD, Collantes Estévez E, Fernández Carballido C, Fernández Sueiro JL, García de Vicuña R, González-Álvaro I, González Fernández C, Juanola X, Linares LF, Marenco JL, Martín Mola E, Moreno Ramos M, Mulero Mendoza J, Muñoz Fernández S, Queiro R, Richi Alberti P, Sanz J, Tornero Molina J, Zarco Montejo P, Carmona L; Sociedad Española de Reumatología.

Reumatol Clin. 2011 Sep-Oct;7(5):284-98. doi: 10.1016/j.reuma.2011.05.002. Epub 2011 Aug 4. Spanish.

19.

[Treatment of cardiovascular risk factors].

Krüger K.

Z Rheumatol. 2016 Mar;75(2):173-80; quiz 181-2. doi: 10.1007/s00393-016-0064-8. German. Erratum in: Z Rheumatol. 2016 Jun;75(5):489.

PMID:
26924198
20.

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.

Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.

Rheumatology (Oxford). 2009 Nov;48(11):1451-4. doi: 10.1093/rheumatology/kep270. Epub 2009 Sep 11.

PMID:
19748965

Supplemental Content

Support Center